D-0246-2021 Class II Terminated

Recalled by Taro Pharmaceuticals U.S.A., Inc. — Hawthorne, NY

FDA drug recall D-0246-2021 was initiated by Taro Pharmaceuticals U.S.A., Inc. on Jan 8, 2021 and is designated Class II. Reason for recall: CGMP deviations. The recall status is terminated (terminated Sep 7, 2023). Affected quantity: 44,256 bottles.

Recall details

Product Type
Drugs
Report Date
Feb 10, 2021
Initiation Date
Jan 8, 2021
Termination Date
Sep 7, 2023
Voluntary/Mandated
Voluntary: Firm initiated
Product Quantity
44,256 bottles

Product description

Nortriptyline HCl Capsules, USP equivalent to 10mg base Mfd. by: Taro Pharmaceutical Industries Ltd. Haifa Bay, Israel 2624761 Dist. by: Taro Pharmaceuticals U.S.A., Inc. Hawthorne, NY 10532 NDC 51672-4001-1

Reason for recall

CGMP deviations.

Distribution pattern

Nationwide

Code information

AC05096, AC05098, and AC05099; Exp 10/31/2022

Source

Dataset
openFDA drug recall enforcement reports
FDA record
This recall in openFDA (JSON)
Enforcement Report
Search FDA's Enforcement Report for D-0246-2021
openFDA file date
Nov 10, 2026
Loaded by RegDataLab
Nov 11, 2026

These dates say when openFDA published the data file and when RegDataLab last loaded it.

Source: openFDA record for D-0246-2021. Report a data issue: hello@regdatalab.com.